Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (61)

Jan 10, 2043method-of-use (U-4088)US 12186306
Aug 13, 2040compositionUS 11873300
Aug 13, 2040compositionUS 11873300
Feb 14, 2039compositionUS 11066417
Feb 14, 2039compositionUS 11066417
Feb 14, 2039method-of-use (U-4082)US 11866450
Feb 14, 2039method-of-use (U-4082)US 11866450
Apr 14, 2035formulationUS 10206877
Apr 14, 2035formulationUS 11951212
Jul 15, 2033method-of-use (U-4218)US 10058546
Jul 15, 2033method-of-use (U-4097)US 9012496
May 17, 2032compositionUS 10047053
May 17, 2032compositionUS 10047053
May 17, 2032compositionUS 8865902
May 17, 2032compositionUS 8865902
May 17, 2032compositionUS 9181192
May 17, 2032compositionUS 9181192
May 17, 2032compositionUS 9512079
May 17, 2032compositionUS 9512079
Jul 10, 2031compositionUS RE504534.8y
Jul 10, 2031compositionUS RE504534.8y
Mar 25, 2031formulationUS 100816214.5y
Mar 25, 2031formulationUS 100816214.5y
Mar 25, 2031formulationUS 115780624.5y
Mar 25, 2031formulationUS 115780624.5y
Aug 13, 2029formulationUS 106464812.9y
Aug 13, 2029formulationUS 106464812.9y
Aug 13, 2029method-of-use (U-4095)US 115649162.9y
Aug 13, 2029method-of-use (U-4095)US 115649162.9y
Nov 12, 2027method-of-use (U-4082)US 84153871.1y
Nov 12, 2027method-of-use (U-4082)US 84153871.1y
Aug 5, 2027method-of-use (U-4090)US 8324242306d
Aug 5, 2027method-of-use (U-4090)US 8324242306d
Jun 3, 2027compositionUS 7776905243d
Jun 3, 2027compositionUS 7776905243d
May 20, 2027compositionUS 7495103229d
May 20, 2027compositionUS 7495103229d
May 1, 2027compositionUS 7645789210d
May 1, 2027compositionUS 7645789210d
May 1, 2027method-of-use (U-4090)US 8598181210d
May 1, 2027method-of-use (U-4090)US 8598181210d
May 1, 2027compositionUS 8623905210d
May 1, 2027compositionUS 8623905210d
Apr 9, 2027formulationUS 10022352188d
Apr 9, 2027formulationUS 10022352188d
Apr 9, 2027compositionUS 10239867188d
Apr 9, 2027compositionUS 10239867188d
Apr 9, 2027compositionUS 11639347188d
Apr 9, 2027compositionUS 11639347188d
Apr 9, 2027formulationUS 9974781188d
Apr 9, 2027formulationUS 9974781188d
Dec 28, 2026formulationUS 841027486d
Dec 28, 2026formulationUS 841027486d
Dec 28, 2026compositionUS 875422486d
Dec 28, 2026compositionUS 875422486d
Dec 28, 2026formulationUS 967016386d
Dec 28, 2026formulationUS 967016386d
Dec 28, 2026formulationUS 993133486d
Dec 28, 2026formulationUS 993133486d
Jul 6, 2026method-of-use (U-4091)US 8354427
Jul 6, 2026method-of-use (U-4091)US 8354427

FDA exclusivities (2)

Dec 20, 2029NCENew Chemical Entity (5y)3.2y
Dec 20, 2029NCENew Chemical Entity (5y)3.2y

News(5)

ReCode CEO Suliman leaves cystic fibrosis mission in mentee’s hands
After achieving clinical validation earlier this year, ReCode Therapeutics has called up a new CEO to take on the mission of advancing programs for cystic fibrosis and primary ciliary dyskinesia th…
biospace · 9d ago
Lilly pens $370M deal with OmniAb for ion channel collab, but details remain vague
Antibody platform business OmniAb continues to rack up Big Pharma partnerships, with Eli Lilly signing off on up to $370 million biobucks tied to an ion channel program.
fiercebiotech · 1mo ago
Sionna’s cystic fibrosis failure is a windfall for Vertex’s blockbuster franchise
A surprise flop in Phase 2a cystic fibrosis trial sent Sionna’s shares plummeting, but for Vertex, the news reinforced its standard-of-care standing with highly successful drugs like Trikafta.
biospace · 1mo ago
Vertex’s biggest overhang: a rival 50 times smaller
Despite another strong earnings report, analysts warned that upcoming cystic fibrosis data from Sionna Therapeutics "looms large" over Vertex.
biopharma_dive · 1mo ago
Vertex earnings get muted investor response
While overall revenue fell just shy of Wall Street forecasts, sales of the gene editing medicine Casgevy and pain drug Journavx missed analyst estimates by double-digit percentages.
biopharma_dive · 5mo ago

brand

Alyftrek

generic

(deutivacaftor + tezacaftor + vanzacaftor calcium)

MOA

12.1 Mechanism of Action Vanzacaftor and tezacaftor bind to different sites on the CFTR protein and have an additive effect in facilitating the cellular processing and trafficking of select mutant forms of CFTR (including F508del- CFTR) to increase the amount of CFTR protein delivered to the cell surface compared to either molecule alone. Deutivacaftor potentiates the channel open probability (or gating) of the CFTR protein at the cell surface. The combined effect of vanzacaftor, tezacaftor and deutivacaftor is increased quantity and function of CFTR at the cell surface, resulting in increased CFTR activity as measured both by CFTR-mediated chloride transport in vitro and by sweat chloride in patients with CF. CFTR Chloride Transport Assay in Fischer Rat Thyroid Cells Expressing Mutant CFTR Protein Effects of vanzacaftor/tezacaftor/deutivacaftor on chloride transport for mutant CFTR protein was determined in Ussing chamber electrophysiology studies using a panel of Fischer Rat Thyroid (FRT) cell lines stably expressing CFTR protein from individual variants. Vanzacaftor/tezacaftor/deutivacaftor increased chloride transport in FRT cells expressing select CFTR variants, as identified in Table 5. The threshold that the treatment-induced increase in chloride transport must exceed for the mutant CFTR protein to be considered responsive is ≥10% of normal over baseline. This threshold was used because it is expected to predict clinical benefit. For individual variants, the magnitude of the net change over baseline in CFTR-mediated chloride transport in vitro is not correlated with the magnitude of clinical response. CFTR Chloride Transport Assay in Human Bronchial Epithelial Cells Expressing Mutant CFTR Protein Homozygous and heterozygous N1303K- Human Bronchial Epithelial (HBE) cells showed greater chloride transport in the presence of vanzacaftor/tezacaftor/deutivacaftor than F508del/F508del- HBE cells treated with tezacaftor/ivacaftor which has shown clinical benefit in

indication

Cystic Fibrosis

phase

marketed

Data sources

openFDA · ClinicalTrials.gov

last refreshed 4h ago

Found something off?

comments(0)

5-min edit window · permanent after that

no comments yet — first sniff?

News(5)

ReCode CEO Suliman leaves cystic fibrosis mission in mentee’s hands

After achieving clinical validation earlier this year, ReCode Therapeutics has called up a new CEO to take on the mission of advancing programs for cystic fibrosis and primary ciliary dyskinesia th…

biospace · 9d ago

Lilly pens $370M deal with OmniAb for ion channel collab, but details remain vague

Antibody platform business OmniAb continues to rack up Big Pharma partnerships, with Eli Lilly signing off on up to $370 million biobucks tied to an ion channel program.

fiercebiotech · 1mo ago

Sionna’s cystic fibrosis failure is a windfall for Vertex’s blockbuster franchise

A surprise flop in Phase 2a cystic fibrosis trial sent Sionna’s shares plummeting, but for Vertex, the news reinforced its standard-of-care standing with highly successful drugs like Trikafta.

biospace · 1mo ago

Vertex’s biggest overhang: a rival 50 times smaller

Despite another strong earnings report, analysts warned that upcoming cystic fibrosis data from Sionna Therapeutics "looms large" over Vertex.

biopharma_dive · 1mo ago

Vertex earnings get muted investor response

While overall revenue fell just shy of Wall Street forecasts, sales of the gene editing medicine Casgevy and pain drug Journavx missed analyst estimates by double-digit percentages.

biopharma_dive · 5mo ago

(deutivacaftor + tezacaftor + vanzacaftor calcium)

🐶 often sniffed alongside

indications

all catalysts(4)

Patent cliff

patents (61)

FDA exclusivities (2)

News(5)

Report a data issue

comments(0)

(deutivacaftor + tezacaftor + vanzacaftor calcium)

🐶 often sniffed alongside

indications

all catalysts(4)

Patent cliff

patents (61)

FDA exclusivities (2)

News(5)

Report a data issue

comments(0)